Clinical trial
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of HEC113995 PA•H2O Tablets in Healthy Subjects
NCT04591301 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of HEC113995 PA•H2O Tablets in Healthy Subjects
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 4, 2019
- Completion date
- December 6, 2019
- Enrollment
- 69 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.